[1] O’Connell, M.B.; Vondracek, S.F. Osteoporosis and other metabolic bone diseases, in Pharmacotherapy: A Pathophysiologic Approach. 7th ed (Dipiro, J.T.; Talbert, R.L.; Yee, G.C.; Matzke, G.R.; Wells, B.G.; Posey, L.M. Eds.), New York, McGraw Hill, 2008, 1483-1504.
[2] Chiechi, L.M.; Micheli, L. Curr. Top. Nutraceut. Res. 2005, 3, 15-28.
[3] Mithal, A.; Ebeling, P.; Kyer, C.S. The Asia-Pasific regional audit: epidemiology, cost & burden of osteoporosis in 2013. Switzerland: International Osteoporosis Foundation. 2013, 56-60.
[4] Xu, S.; Li, N.; Ning, M.M.; Zhou, C.H.; Yang, Q.R.; Wang, M.W. J. Nat. Prod. 2006, 69, 247-250.
[5] Ngueguim, F.T.; Khan, M.P.; Donfack, J.H.; Tewari, D.; Dimo, T.; Maurya, R.; Chattopadhyay, N. J. Ethnopharmacol. 2013, 148, 62-68.
[6] Gitelman, H.J. Anal. Biochem. 1967, 18, 521-531.
[7] Jiang, J.M.Y.; Sacco, S.M.; Ward, W.E. J. Nutr. 2008, 138, 2106-2110.
[8] Lim, D.W.; Kim, J.G.; Lee, Y.; Cha, S.H.; Kim, Y.T. Molecules. 2013, 18, 7998-8008.
[9] Kini, U.; Nandeesh, B.N. Physiology of bone formation, remodeling, and metabolism, in Radionuclide and Hybrid Bone Imaging (Fogelman, I.; Gnanasegaran, G.; Van der Wall, H. Eds.), Springer-Verlag, Berlin, 2012, 132.
[10] Dick, I.M.; Devine, A.; Beilby, J.; Prince, R.L. Am. J. Physiol. Endocrinol. Metab. 2005, 288, 430-435.
[11] Ooi, D.J.; Iqbal, S.; Ismail, M. Molecules. 2012, 17, 11139-11145.
[12] Riggs, B.L. J. Clin. Invest. 2000, 106, 1203-1204. |